Active ingredientFasiglifamCat. No. P-F007-001CAS 1000413-72-8Family · Pharmaceutical analytical standards
Fasiglifam
An experimental antidiabetic that activates the GPR40 (FFAR1) receptor of pancreatic beta cells, stimulating insulin release. Developed in Japan for type 2 diabetes, it was stopped in phase III at the end of 2013. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Its target, GPR40, is a fat 'sensor': in nature it is switched on by medium- and long-chain fatty acids, including the omega-3s DHA and EPA.
Go to the active ingredient →Active ingredientFasiglifamCat. No. P-F007-001CAS 1000413-72-8
Isotopically labelledFasiglifam -13C-d3Cat. No. P-F007-002
Impurityent-FasiglifamCat. No. P-F007-003CAS 1234474-57-7
ImpurityFasiglifam Impurity 1Cat. No. P-F007-004CAS 1000413-85-3
Impurityrac-FasiglifamCat. No. P-F007-005CAS 1390641-84-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.